Developer docs
API playgroundTry for free, no card

Search company profiles

Athyrium Capital Management LP

Full company profile

uuid0000t13

Namestring
Athyrium Capital Management LP
Legal namestring
Athyrium Capital Management, LP
Websiteurl
athyrium.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Athyrium Capital Management LP is a specialized healthcare-focused investment management firm founded in 2008 and headquartered at 505 Fifth Avenue, New York City. The firm provides structured financing solutions—including direct lending, acquisition financing, royalty monetization, and special situations investments—to commercial-stage healthcare companies globally. Its investment universe spans biotechnology, pharmaceuticals, healthcare services, healthcare technology, and medical devices, with individual investment sizes up to $200 million and the ability to upsize opportunistically.

Athyrium manages four flagship vehicles—Athyrium Opportunities Funds I through IV—with over $4.6 billion of committed capital and has invested more than $5 billion across 85+ portfolio companies since inception. The firm operates a B2B institutional model, serving two customer constituencies: portfolio companies (as financing provider) and limited partners (institutional investors including public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds). Revenue is generated through management fees on advised funds under multi-year recurring structures.

The firm maintains a longstanding 2009 strategic partnership with Neuberger Berman, which provides institutional LP distribution and co-manages healthcare credit vehicles. Athyrium's investment team of 20+ professionals is led by Managing Partner Jeffrey A. Ferrell (founder, 25+ years of life sciences investing experience, Harvard) and Partner Laurent D. Hermouet (founding member, CFA), supported by senior advisors with operating backgrounds at Cubist, Mylan, Cigna, and other major healthcare companies.

Short descriptiontext

Athyrium Capital Management is a New York-based, healthcare-focused asset manager founded in 2008 that manages $4.6B+ across four funds. It provides structured financing—direct lending, royalties, acquisition financing, and convertible notes—to 85+ commercial-stage biotech, pharma, and healthcare companies globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare asset management, structured healthcare financing, direct lending services, royalty financing solutions, special situations investing
Industry3 codes
PRIMARYFSAAABAD
Advisory Portfolio Management (Non-Discretionary)
Financial & Insurance/Asset & Wealth Management/Private Banking & HNW/UHNW Wealth Management
SECONDARYFSAEALAI
Institutional Capital Introduction (LP/Family Office/Endowment Matching)
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Placement Agents & Capital Raising Intermediation
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory
NAICS code3 codes
  • Portfolio Management and Investment Advice52394
  • Other Financial Vehicles52599
  • Other Investment Pools and Funds5259
SIC code2 codes
  • Investment Advice6282
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Healthcare Asset Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Asset Management Fees
TypeSubscription Recurring
Description

Athyrium earns management fees by advising funds with over $4.6 billion of committed capital. The firm manages multiple investment vehicles including Athyrium Opportunities Funds I-IV and has partnered with Neuberger Berman on healthcare credit strategies.

athyrium.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Fund management services for institutional investors
ModelOtherBilling cadenceMulti-year contract
Notes

Institutional investors including public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds

athyrium.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Athyrium Capital Management is a specialized healthcare-focused investment management firm that manages multiple private investment funds (Athyrium Opportunities Funds I–IV) with over $4.6 billion of committed capital. The firm provides structured financing solutions including direct lending, acquisition financing, growth capital, royalty monetization, and special situations investments to commercial-stage healthcare and life sciences companies globally, with individual investments of up to $200 million per transaction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • $5 billion+ in capital invested across 85+ portfolio companies since founding in 2008
Product overview1 text field

Athyrium Capital Management LP is a specialized healthcare investment management platform that offers structured financing solutions and investment vehicles across the healthcare and life sciences sectors. The firm operates multiple fund vehicles (Athyrium Opportunities Fund I, II, III, and IV) providing flexible capital to public and private healthcare companies. The platform focuses on biotechnology, pharmaceuticals, healthcare services, healthcare technology, and medical devices/products sectors, offering growth financing, debt instruments, royalty monetization, and structured investments to portfolio companies with committed capital exceeding $4.6 billion.

Product and service5 records
1Athyrium Opportunities Fund I
CategoryFund Vehicle
2Athyrium Opportunities Fund II
CategoryFund Vehicle
3Athyrium Opportunities Fund III
CategoryFund Vehicle
4Athyrium Opportunities Fund IV
CategoryFund Vehicle
5Healthcare Investment Management Platform
CategoryCore Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Royalty Pharma is the largest healthcare royalty buyer and a publicly listed leader in biopharma royalty financing. While larger and more focused on larger/mega-deal royalties than Athyrium, it is a directly comparable buyer of healthcare cash-flow streams (e.g., the BioCryst $325M funding alongside Athyrium).

TypeRegional player
Description

Avista Capital Partners is a healthcare-focused private equity firm (and a former employer of Athyrium Partner Mark Kavulich). It pursues growth equity and buyouts in healthcare, overlapping thematically with Athyrium's growth capital and structured equity transactions in the healthcare sector.

TypeBroad incumbent
Description

OrbiMed is one of the largest dedicated healthcare investment firms across private equity, venture, and royalty/credit strategies. It overlaps with Athyrium in healthcare private credit and structured capital while operating a much broader, multi-strategy platform.

TypeDirect peer
Description

NovaQuest is a specialist asset manager focused on structured financing and royalty monetization for life sciences companies, with a similar product mix (royalty, milestone, debt) and healthcare-only mandate as Athyrium. It is one of the closest direct competitors in mid-market healthcare structured capital.

TypeBroad incumbent
Description

Blackstone Life Sciences is the life sciences arm of Blackstone investing across private equity, credit, and royalties in biopharma. It is a scaled incumbent competing for healthcare structured finance opportunities alongside Athyrium.

TypeDirect peer
Description

HealthCare Royalty Partners is a healthcare-focused structured finance and royalty investment firm that provides capital to healthcare and life sciences companies, directly overlapping with Athyrium's healthcare credit, royalty, and structured equity strategy. The two firms have even co-invested (e.g., Portola Pharmaceuticals $125M loan in 2019).

TypeBroad incumbent
Description

KKR's healthcare platform invests across healthcare services, pharma, and life sciences credit. Its scale, multi-product offerings, and institutional LP access make it a comparable broad incumbent in healthcare credit and growth investing.

TypeDirect peer
Description

BioPharma Credit is a publicly traded specialty finance investor focused on debt and royalty financing for the biopharma sector. Its exclusive healthcare credit mandate mirrors Athyrium's strategy and target issuer base.

TypeDirect peer
Description

Pharmakon Advisors is a healthcare-focused structured capital provider offering senior secured loans and royalty-style financing to commercial-stage life sciences companies, with a product mix very similar to Athyrium's direct lending and royalty offerings.

TypeEmerging player
Description

BridgeBio operates as a genetic disease-focused biotech but has built a sizable balance sheet and structured financing relationships. As an emerging, healthcare-focused capital allocator with growing financing activities, it is a thematic adjacent peer in the healthcare credit ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment46 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Athyrium Capital Management LP

Healthcare Asset Managementathyrium.com

Athyrium Capital Management is a New York-based, healthcare-focused asset manager founded in 2008 that manages $4.6B+ across four funds. It provides structured financing—direct lending, royalties, acquisition financing, and convertible notes—to 85+ commercial-stage biotech, pharma, and healthcare companies globally.

What Athyrium Capital Management LP does

Athyrium Capital Management LP is a specialized healthcare-focused investment management firm founded in 2008 and headquartered at 505 Fifth Avenue, New York City. The firm provides structured financing solutions—including direct lending, acquisition financing, royalty monetization, and special situations investments—to commercial-stage healthcare companies globally. Its investment universe spans biotechnology, pharmaceuticals, healthcare services, healthcare technology, and medical devices, with individual investment sizes up to $200 million and the ability to upsize opportunistically.

Athyrium manages four flagship vehicles—Athyrium Opportunities Funds I through IV—with over $4.6 billion of committed capital and has invested more than $5 billion across 85+ portfolio companies since inception. The firm operates a B2B institutional model, serving two customer constituencies: portfolio companies (as financing provider) and limited partners (institutional investors including public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds). Revenue is generated through management fees on advised funds under multi-year recurring structures.

The firm maintains a longstanding 2009 strategic partnership with Neuberger Berman, which provides institutional LP distribution and co-manages healthcare credit vehicles. Athyrium's investment team of 20+ professionals is led by Managing Partner Jeffrey A. Ferrell (founder, 25+ years of life sciences investing experience, Harvard) and Partner Laurent D. Hermouet (founding member, CFA), supported by senior advisors with operating backgrounds at Cubist, Mylan, Cigna, and other major healthcare companies.

Athyrium Capital Management LP firmographics

Firmographics
Name
Athyrium Capital Management LP
Legal name
Athyrium Capital Management, LP
Website
https://athyrium.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Athyrium Capital Management is a New York-based, healthcare-focused asset manager founded in 2008 that manages $4.6B+ across four funds. It provides structured financing—direct lending, royalties, acquisition financing, and convertible notes—to 85+ commercial-stage biotech, pharma, and healthcare companies globally.
Ownership category
akta.pro rank

Athyrium Capital Management LP industry classification

Industry
Product category
Healthcare Asset Management
NAICS
Portfolio Management and Investment Advice (52394), Other Financial Vehicles (52599), Other Investment Pools and Funds (5259)
SIC
Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
akta.pro industry
PRIMARYFSAAABAD
Advisory Portfolio Management (Non-Discretionary)
Financial & Insurance/Asset & Wealth Management/Private Banking & HNW/UHNW Wealth Management
SECONDARYFSAEALAI
Institutional Capital Introduction (LP/Family Office/Endowment Matching)
Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Placement Agents & Capital Raising Intermediation
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory

Keywords

  • Healthcare asset management
  • Structured healthcare financing
  • Direct lending services
  • Royalty financing solutions
  • Special situations investing

Where Athyrium Capital Management LP is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Athyrium Capital Management LP business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Asset Management Fees: Athyrium earns management fees by advising funds with over $4.6 billion of committed capital. The firm manages multiple investment vehicles including Athyrium Opportunities Funds I-IV and has partnered with Neuberger Berman on healthcare credit strategies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFund management services for institutional investors

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Athyrium Capital Management LP product offering

Product offering

Core offering

Athyrium Capital Management is a specialized healthcare-focused investment management firm that manages multiple private investment funds (Athyrium Opportunities Funds I–IV) with over $4.6 billion of committed capital. The firm provides structured financing solutions including direct lending, acquisition financing, growth capital, royalty monetization, and special situations investments to commercial-stage healthcare and life sciences companies globally, with individual investments of up to $200 million per transaction.

Product overview

Athyrium Capital Management LP is a specialized healthcare investment management platform that offers structured financing solutions and investment vehicles across the healthcare and life sciences sectors. The firm operates multiple fund vehicles (Athyrium Opportunities Fund I, II, III, and IV) providing flexible capital to public and private healthcare companies. The platform focuses on biotechnology, pharmaceuticals, healthcare services, healthcare technology, and medical devices/products sectors, offering growth financing, debt instruments, royalty monetization, and structured investments to portfolio companies with committed capital exceeding $4.6 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • Athyrium Opportunities Fund I
  • Athyrium Opportunities Fund II
  • Athyrium Opportunities Fund III
  • Athyrium Opportunities Fund IV
  • Healthcare Investment Management Platform

Quantifiable outcome

  • $5 billion+ in capital invested across 85+ portfolio companies since founding in 2008

Companies that use Athyrium Capital Management LP

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles2 records

Athyrium Capital Management LP technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Athyrium Capital Management LP partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Athyrium Capital Management LP competitors and assessment

Company assessment

Broad incumbents

  • Royalty Pharma: Royalty Pharma is the largest healthcare royalty buyer and a publicly listed leader in biopharma royalty financing. While larger and more focused on larger/mega-deal royalties than Athyrium, it is a directly comparable buyer of healthcare cash-flow streams (e.g., the BioCryst $325M funding alongside Athyrium).
  • OrbiMed: OrbiMed is one of the largest dedicated healthcare investment firms across private equity, venture, and royalty/credit strategies. It overlaps with Athyrium in healthcare private credit and structured capital while operating a much broader, multi-strategy platform.
  • Blackstone Life Sciences: Blackstone Life Sciences is the life sciences arm of Blackstone investing across private equity, credit, and royalties in biopharma. It is a scaled incumbent competing for healthcare structured finance opportunities alongside Athyrium.
  • KKR Health Care Strategic Growth: KKR's healthcare platform invests across healthcare services, pharma, and life sciences credit. Its scale, multi-product offerings, and institutional LP access make it a comparable broad incumbent in healthcare credit and growth investing.

Regional players

  • Avista Capital Partners: Avista Capital Partners is a healthcare-focused private equity firm (and a former employer of Athyrium Partner Mark Kavulich). It pursues growth equity and buyouts in healthcare, overlapping thematically with Athyrium's growth capital and structured equity transactions in the healthcare sector.

Direct peers

  • NovaQuest Capital Management: NovaQuest is a specialist asset manager focused on structured financing and royalty monetization for life sciences companies, with a similar product mix (royalty, milestone, debt) and healthcare-only mandate as Athyrium. It is one of the closest direct competitors in mid-market healthcare structured capital.
  • HealthCare Royalty Partners: HealthCare Royalty Partners is a healthcare-focused structured finance and royalty investment firm that provides capital to healthcare and life sciences companies, directly overlapping with Athyrium's healthcare credit, royalty, and structured equity strategy. The two firms have even co-invested (e.g., Portola Pharmaceuticals $125M loan in 2019).
  • BioPharma Credit: BioPharma Credit is a publicly traded specialty finance investor focused on debt and royalty financing for the biopharma sector. Its exclusive healthcare credit mandate mirrors Athyrium's strategy and target issuer base.
  • Pharmstandard / Pharmakon Advisors: Pharmakon Advisors is a healthcare-focused structured capital provider offering senior secured loans and royalty-style financing to commercial-stage life sciences companies, with a product mix very similar to Athyrium's direct lending and royalty offerings.

Emerging players

  • BridgeBio Pharma Capital: BridgeBio operates as a genetic disease-focused biotech but has built a sizable balance sheet and structured financing relationships. As an emerging, healthcare-focused capital allocator with growing financing activities, it is a thematic adjacent peer in the healthcare credit ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Athyrium Capital Management LP social profiles

Digital presence

Athyrium Capital Management LP financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Athyrium Capital Management LP leadership team

Management profile

Number of profiles

Profiles14 records

Athyrium Capital Management LP funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Athyrium Capital Management LP M&A and investment

M&A and investment

M&A

Investments46 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Athyrium Capital Management LP

What does Athyrium Capital Management LP do?

Athyrium Capital Management is a specialized healthcare-focused investment management firm that manages multiple private investment funds (Athyrium Opportunities Funds I–IV) with over $4.6 billion of committed capital. The firm provides structured financing solutions including direct lending, acquisition financing, growth capital, royalty monetization, and special situations investments to commercial-stage healthcare and life sciences companies globally, with individual investments of up to $200 million per transaction.

Is Athyrium Capital Management LP a public or private company?

Athyrium Capital Management LP is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Athyrium Capital Management LP founded?

Athyrium Capital Management LP was founded in 2008. It employs 11 to 50 people.

Where is Athyrium Capital Management LP based?

Athyrium Capital Management LP is headquartered in New York, United States, in the North America region.

How does Athyrium Capital Management LP make money?

One revenue line is on record: asset Management Fees.

Who are Athyrium Capital Management LP's main competitors?

Broad incumbents on record are Royalty Pharma, OrbiMed, Blackstone Life Sciences and KKR Health Care Strategic Growth. Avista Capital Partners is listed as a regional player. Direct peers are NovaQuest Capital Management, HealthCare Royalty Partners, BioPharma Credit and Pharmstandard / Pharmakon Advisors. BridgeBio Pharma Capital is listed as an emerging player.

Does Athyrium Capital Management LP have an API?

No public API is recorded for Athyrium Capital Management LP.

What industry is Athyrium Capital Management LP in?

Athyrium Capital Management LP's product category is Healthcare Asset Management. Its primary akta.pro industry code is FSAAABAD, Advisory Portfolio Management (Non-Discretionary), with a secondary code of FSAEALAI, Institutional Capital Introduction (LP/Family Office/Endowment Matching). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEsperion sells Japan royalty rights for $50 million to Athyrium By Investing.comEsperion Therapeutics Inc. announced that Athyrium Capital Management purchased royalties from Japan sales of Otsuka Pharmaceutical's bempedoic acid products for $50 million. The proceeds will support Esperion’s acquisition of Corstasis Therapeutics Inc., a company that developed the FDA-approved Enbumyst nasal spray.GlobeNewswireAthyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsAthyrium Capital Management has entered into a $50 million royalty financing agreement with Esperion Therapeutics, acquiring 100% of Esperion's royalty interest on Otsuka's bempedoic acid product net sales in Japan from January 1, 2026, along with related milestone payments. Under the terms, Athyrium Funds will receive tiered royalties ranging from 12% to 33% until aggregate payments reach 2.0x their investment, after which rights revert to Esperion. The financing is specifically designed to support Esperion's acquisition of Corstasis Therapeutics, whose lead asset Enbumyst is the first FDA-approved intranasal loop diuretic.YahooAthyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsAthyrium Capital Management and Esperion Therapeutics entered into a $50 million royalty financing agreement under which Athyrium Funds acquired 100% of Esperion's royalty interest on Otsuka's bempedoic acid products in Japan, with tiered royalties ranging from 12% to 33% until aggregate payments reach 2.0x their investment. The financing provides Esperion with non-dilutive capital to support its acquisition of Corstasis Therapeutics, a commercial-stage cardiovascular company whose lead product Enbumyst is the first FDA-approved intranasal loop diuretic for treating edema associated with cardiovascular, hepatic, and renal disease.GurufocusEsperion (ESPR) Secures $50M Royalty Financing Deal with AthyriuEsperion (ESPR) has secured a $50 million royalty financing agreement with Athyrium Capital Management, under which Athyrium will acquire Esperion's royalty interest on Otsuka Pharmaceutical's net sales of bempedoic acid products in Japan. The non-dilutive capital will fund Esperion's acquisition of Corstasis Therapeutics, a commercial-stage cardiovascular firm offering Enbumyst, the only FDA-approved intranasal loop diuretic for edema related to cardiovascular, hepatic, and renal conditions. This marks Athyrium's second major financial collaboration with Esperion in 16 months, following a previous $150 million senior secured loan facility.MarketScreenerAthyrium Capital Management and Esperion enter into $50 million Japan royalty financing to support strategic acquisition of Corstasis TherapeuticsAthyrium Capital Management and Esperion Therapeutics have entered into a $50 million Japan royalty financing agreement to fund Esperion's strategic acquisition of Corstasis Therapeutics. The transaction provides Esperion with capital in exchange for royalty rights tied to its Japan operations or assets. This financing structure enables Esperion to pursue growth through M&A while securing non-dilutive capital for the deal.Financial TimesSignet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc. – Company AnnouncementA consortium led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Inc. exited its stake in Pharmaceutics International, Inc. and sold the contract development and manufacturing organization to Jabil Inc. in an undisclosed all-cash transaction. Pii, based in Hunt Valley, Maryland, specializes in aseptic and sterile injectable pharmaceutical products.PR NewswireCalliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium CapitalCalliditas Therapeutics AB has announced the signing and full drawdown of a €92 million term loan with Athyrium Capital Management. The loan will be used to repay an existing €68 million loan with Kreos Capital and extends the interest-only period on debt by three years. This refinancing is part of Calliditas's strategy to enhance its financial position and support the commercialization of its product, TARPEYO®, following its full FDA approval.Wayback MachineCalliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital – Calliditas Therapeutics ABCalliditas Therapeutics AB has refinanced its existing term loan with a new senior secured facility amounting to Euro 92 million from Athyrium Capital. This refinancing aims to improve the company's financial structure and potentially enhance its operational capabilities moving forward.